FHTX Foghorn Therapeutics Inc.

CIK 0001822462 50 ready 8-Ks latest August 6, 2026, 7:01 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 6, 2026, 7:01 AM ET

Top materiality 0.80

Event mix other_material ×21 · earnings ×13 · leadership ×8

Sentiment 14 pos · 3 neg · 33 neu

Latest earnings reported 2026-Q2

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for FHTX

Highest-materiality recent filing

Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024

February 8, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.
Lilly plans to file an IND for FHD-909 in Q2 2024 for BRG1 mutated NSCLC.

Read filing →

August 6, 2026, 7:01 AM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01

Foghorn Therapeutics Q2 2026 net loss narrows to $7.2M; cash runway into H1 2028

Net loss of $7.2M vs $17.9M in Q2 2025; collaboration revenue $16.1M (up from $7.6M) due to catch-up adjustment.
May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Foghorn Q1 net loss $19.9M, cash $183.6M; FHD-909 Phase 1 on track; IND for two degraders expected 2027

Q1 2026 net loss $19.9M (vs $18.8M loss Q1 2025); collaboration revenue $3.3M (down from $6.0M).
April 21, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Foghorn presents preclinical data at AACR: FHD-909 combo shows complete regression and immune memory

FHD-909 (SMARCA2 inhibitor) plus anti-PD-1 achieved complete tumor regression and immune memory in preclinical SMARCA4-mutant models.
March 11, 2026, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Foghorn Therapeutics reports 2025 net loss $74.3M, cash runway into H1 2028; pipeline advances

Net loss improved to $74.3M in 2025 from $86.6M in 2024; collaboration revenue rose to $30.9M.
February 23, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 8.01 item 9.01

Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher

Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).
January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01

Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028

Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).
November 5, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 5.02 item 7.01 item 9.01

Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028

CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.
October 30, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 8.01 item 9.01

Foghorn Therapeutics advances three degrader programs; ARID1B degrader selectively degrades ARID1B

Selective ARID1B degrader shows selective binding and degradation, potentially relevant in up to 5% of solid tumors (endometrial, gastric, bladder, NSCLC).
August 5, 2025, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01

Foghorn Therapeutics Q2 2025 net loss narrows to $17.9M; cash runway into 2028; pipeline on track

Net loss of $17.9M in Q2 2025, improved from $23.0M in Q2 2024; collaboration revenue $7.6M.
July 1, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 1.02 item 9.01

Foghorn Therapeutics signs new 9-year lease for 72,846 sq ft HQ in Watertown, MA, terminates Cambridge lease

New lease at 99 Coolidge Avenue, Watertown for 72,846 sq ft; annual base rent starts at $87/sq ft with partial abatement in years 1-2.
May 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs

Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).
April 28, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing

FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.
March 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Foghorn Therapeutics reports 2024 net loss $86.6M; cash runway into 2027; key pipeline milestones

Net loss of $86.6M for FY2024 vs $98.4M in 2023; collaboration revenue $22.6M (down from $34.2M).
January 13, 2025, 6:59 PM ET other material materiality 0.65 positive item 2.02 item 7.01 item 9.01

Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders

Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.
December 16, 2024, 6:59 PM ET other material materiality 0.65 negative item 7.01 item 8.01 item 9.01

Foghorn discontinues FHD-286 in AML; prioritizes pipeline and Lilly collaboration

FHD-286 + decitabine showed objective responses in Phase 1 but efficacy threshold not met for continued standalone development.
November 4, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909

Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.
October 10, 2024, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 8.01 item 9.01

Foghorn Therapeutics announces first patient dosed with FHD-909 in Phase 1 trial for SMARCA4 mutated cancers

First patient dosed with FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor, in Phase 1 trial for SMARCA4 mutated solid tumors.
August 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01

Foghorn reports Q2 net loss $23M; cash $285M into 2027; FHD-286 AML data Q4; FHD-909 first patient H2 2024

Net loss $23.0M for Q2 2024 vs $29.5M in Q2 2023; collaboration revenue $6.9M.
May 22, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Foghorn Therapeutics raises ~$110M via public offering of common stock and pre-funded warrants

Sold 12,743,039 shares of common stock at $5.51/share and pre-funded warrants for 7,220,794 shares at $5.5099 each.
April 16, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change ×2

Foghorn appoints Kristian Humer as CFO; notes upcoming pipeline milestones for 2024

Kristian Humer appointed CFO effective April 16, replacing interim CFO Stephen DiPalma.
April 9, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Foghorn reports preclinical AACR data for FHD-909, CBP/EP300 degraders; IND on track Q2 2024

FHD-909, a first-in-class BRM selective inhibitor, shows ~30-fold selectivity over BRG1 and dose-dependent tumor growth inhibition in BRG1 mutant xenografts.
March 7, 2024, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024

Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.
February 8, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Foghorn announces Lilly selects FHD-909 for clinical development; IND planned for Q2 2024

Lilly selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development.
November 2, 2023, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Foghorn Therapeutics Q3 net loss narrows to $14.3M; cash runway into H1 2026

Net loss $14.3M vs $25.8M YoY; collaboration revenue $17.5M incl. Merck termination.
August 10, 2023, 7:59 PM ET other material materiality 0.70 negative item 1.02 ◈ Material Agreements

Foghorn Therapeutics receives notice from Merck terminating collaboration agreement effective Nov 7, 2023

Merck terminates Research Collaboration and Exclusive License Agreement effective November 7, 2023, citing internal portfolio prioritization.
August 8, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 8.01 item 9.01

Foghorn Therapeutics appoints Alfonso Quintás-Cardama as CMO; Sam Agresta departs Sept 11, 2023

Samuel Agresta steps down as CMO effective September 11, 2023; will consult through early January 2024.
August 4, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Foghorn Therapeutics Q2 net loss $29.5M; cash $284.3M; AML combo study starting Q3 2023

Net loss of $29.5M for Q2 2023 vs $27.3M in Q2 2022.
June 28, 2023, 7:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

Foghorn Therapeutics reports Phase 1 data for FHD-286 in uveal melanoma, will not advance independently

Phase 1 dose escalation study of FHD-286 in 73 metastatic uveal melanoma patients showed safety and tolerability; most common adverse events were dysgeusia, fatigue, AST increase.